Trial Profile
Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Esomeprazole (Primary)
- Indications Anaemia; Beta-thalassaemia; Congenital-dyserythropoietic-anemia; Haemochromatosis; Iron overload; Sickle cell anaemia; Sideroblastic anaemia
- Focus Therapeutic Use
- Acronyms PPI Shine Again
- 21 Oct 2021 Status changed from active, no longer recruiting to completed.
- 23 Jun 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 06 Nov 2019 According to trial design released at 61st Annual Meeting and Exposition of the American Society of Hematology, Results are expected Q3 2020. The trial is funded by ZonMW, The Netherlands Organization for Health and Research Development, and by the Innovatiefonds Zorgverzekeraars.